Minulet (Ethinylestradiol, Gestodene)

Ethinylestradiol is a synthetic estrogen that stabilises the endometrial lining, while gestodene is a progestogen that suppresses the hypothalamic‑pituitary‑ovarian axis. Together they prevent the luteinising hormone surge, block ovulation, thicken cervical mucus and modify the endometrium, reducing the chance of fertilisation and implantation.

The dosing regimen for Minulet is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are provided by the prescriber based on individual patient needs.

Minulet is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued. While limited data exist for breastfeeding, most guidelines advise caution; a healthcare provider should assess the risk‑benefit balance before use in lactating women.

To order Minulet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minulet contains ethinylestradiol paired with gestodene, a third‑generation progestogen that is associated with a lower incidence of androgenic side effects such as acne. Compared with older formulations using levonorgestrel, gestodene may offer improved cycle control and a more favourable bleeding profile, while maintaining similar contraceptive efficacy.

Minulet tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Minulet is taken orally, usually as one tablet each day, at the same time each day. The tablets are swallowed whole with water and should be started on the first day of the menstrual cycle or as directed by a healthcare professional.

Serious risks associated with Minulet include venous thromboembolism, stroke, myocardial infarction and severe allergic reactions. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, sudden severe headache, visual changes, or signs of anaphylaxis such as swelling of the face or throat.

Minulet is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known or suspected breast cancer, active liver disease, or those who are pregnant. It should also be avoided in smokers over 35 years of age and in individuals taking medications that markedly reduce contraceptive effectiveness.